New tool aims to boost HIV prevention in Women's health clinics
NCT ID NCT06684613
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This study tests a decision aid that helps women in sexual and reproductive health clinics decide whether to take PrEP, a daily pill that prevents HIV. Fifty women who are HIV-negative, not on PrEP, and have a uterus will use the aid during a counseling visit. Researchers will measure how often PrEP is prescribed and how well the tool fits into clinic routines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REPRODUCTIVE HEALTH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale Clinical and Community Research
RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PrEP Decision Aid (device)
What this could lead to
If successful, this decision aid could help more women at risk of HIV start PrEP, reducing new infections.
What could go wrong
This is a small, early feasibility study with only 50 participants, so results may not apply broadly. The decision aid may not change behavior more than a standard video.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.